- Home
- VYGR vs NKSH Comparison
VYGR vs NKSH Comparison
Compare VYGR & NKSH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYGR
- NKSH
- Stock Information
- Founded
- VYGR 2013
- NKSH 1891
- Country
- VYGR United States
- NKSH United States
- Employees
- VYGR N/A
- NKSH N/A
- Industry
- VYGR Biotechnology: Pharmaceutical Preparations
- NKSH Major Banks
- Sector
- VYGR Health Care
- NKSH Finance
- Exchange
- VYGR Nasdaq
- NKSH Nasdaq
- Market Cap
- VYGR 206.9M
- NKSH 172.6M
- IPO Year
- VYGR 2015
- NKSH N/A
- Fundamental
- Price
- VYGR $3.36
- NKSH $31.49
- Analyst Decision
- VYGR Strong Buy
- NKSH Strong Buy
- Analyst Count
- VYGR 7
- NKSH 1
- Target Price
- VYGR $14.50
- NKSH $38.00
- AVG Volume (30 Days)
- VYGR 725.5K
- NKSH 14.5K
- Earning Date
- VYGR 08-06-2025
- NKSH 08-13-2025
- Dividend Yield
- VYGR N/A
- NKSH 4.79%
- EPS Growth
- VYGR N/A
- NKSH 15.57
- EPS
- VYGR N/A
- NKSH 1.77
- Revenue
- VYGR $42,580,000.00
- NKSH $49,801,000.00
- Revenue This Year
- VYGR N/A
- NKSH $2.95
- Revenue Next Year
- VYGR $107.07
- NKSH $9.97
- P/E Ratio
- VYGR N/A
- NKSH $17.77
- Revenue Growth
- VYGR N/A
- NKSH 16.22
- 52 Week Low
- VYGR $2.65
- NKSH $23.75
- 52 Week High
- VYGR $8.28
- NKSH $32.89
- Technical
- Relative Strength Index (RSI)
- VYGR 49.16
- NKSH 68.25
- Support Level
- VYGR $3.30
- NKSH $30.09
- Resistance Level
- VYGR $3.49
- NKSH $30.78
- Average True Range (ATR)
- VYGR 0.21
- NKSH 0.80
- MACD
- VYGR -0.02
- NKSH 0.27
- Stochastic Oscillator
- VYGR 33.33
- NKSH 100.00
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
About NKSH National Bankshares Inc.
National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural, commercial real estate, construction for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary, National Bankshares Financial Services, Inc. The company earns its revenues from interest and fees on loans, non-interest income, and investments.